Oculis Holding AG (NASDAQ:OCS) is set to showcase its late-stage ophthalmology pipeline at the 44th Annual J.P. Morgan Healthcare Conference on January 14, following a pivotal start to the year.
Genprex (NASDAQ:GNPX) issued a clinical update on January 7, 2026, for its diabetes gene therapy program, highlighting significant preclinical progress and regulatory advancements for GPX-002.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).
Merck & Co. (NYSE:MRK) began a late-stage clinical trial for a new combination therapy aimed at untreated lung cancer, seeking to eliminate the need for traditional chemotherapy and intravenous infusions for patients with a specific genetic mutation.
Merck & Co. (NYSE:MRK) completed its acquisition of Cidara Therapeutics on Wednesday, following a successful tender offer that values the biotechnology firm at approximately $9 billion.
Compass Pathways (NASDAQ:CMPS) reached a pivotal milestone on Wednesday, January 7, 2026, as the U.S. FDA accepted the company’s Investigational New Drug (IND) application for COMP360, its proprietary synthetic psilocybin treatment, for the treatment of Post-Traumatic Stress Disorder (PTSD).
Alcon (NYSE:ALC), the global leader in eye care, officially terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ:STAA) on Tuesday, January 6, 2026.
The collapse of the deal, originally valued at $1.5 billion and later raised to approximately $1.6 billion, follows a decisive rejection by STAAR’s stockholders at a special meeting earlier that day.
Ionis Pharmaceuticals (NASDAQ:IONS) shares hovered near 52-week highs Wednesday after partner GSK (NYSE:GSK) announced that its experimental drug, bepirovirsen, successfully met the primary endpoints in two pivotal Phase 3 trials, B-Well 1 and B-Well 2.
Ascentage Pharma (NASDAQ:AAPG) shares were in focus on Tuesday, January 6, 2026, following the announcement that the U.S. FDA has cleared its Investigational New Drug (IND) application for APG-3288.
HUTCHMED (China) Limited (NASDAQ:HCM) shares climbed in after-hours trading Wednesday after the company announced that its novel Syk inhibitor, sovleplenib, met the primary endpoint in the Phase III registration portion of the ESLIM-02 trial.
Marvell Technology said on Tuesday it will buy networking equipment provider XConn Technologies in a deal worth about $540 million, as the chipmaker doubles down on data center hardware amid a race to expand artificial intelligence infrastructure.
Johnson & Johnson (NYSE:JNJ) announced on Tuesday, January 6, 2026, that its Phase 2b JASMINE study of nipocalimab in adults with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and key secondary endpoints.
